Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells

European Journal of Haematology

Volumn 81, Issue 4, 2008, Pages 259-266

  Tong, Hongyan ^a,b   Ren, Yanling ^a,b   Zhang, Fengjuan ^a,b   Jin, Jie ^a,b,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

Acute myeloid leukemia; HHT; JAK2 STAT5; Phosphorylation; Protein tyrosine kinase

Indexed keywords

HOMOHARRINGTONINE; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN TYROSINE KINASE; STAT5 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LEUKEMIA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-X PROTEIN; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HARRINGTONINES; HL-60 CELLS; HUMANS; JANUS KINASE 2; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; MUTATION, MISSENSE; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TYRPHOSTINS;

EID: 51649110473     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01116.x     Document Type: Article

References (28)

1. O'Brien S, Talpaz M, Cortes J, et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic phase chronic myelogenous leukemia. Cancer 2002 94 : 2024 32.
2. Zhou DC, Zittoun R, Marie JP. Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull Cancer 1995 82 : 987 95.
3. Bell BA, Chang MN, Weinstein HJ. A phase II study of homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study. Med Pediatr Oncol 2001 37 : 103 7.
4. Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, Cook P, Baskind P. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 1992 6 : 1185 8.
5. Jin J, Jiang DZ, Mai WY, et al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 2006 20 : 1361 7.
6. Tujebajeva RM, Graifer DM, Karpova GG, Ajtkhozhina NA. Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation. FEBS Lett 1989 257 : 254 6.
7. Zhou JY, Chen DL, Shen ZS, Koeffler HP. Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res 1990 50 : 2031 5.
8. Tang R, Faussat AM, Majdak P, Marzac C, Dubrulle S, Marjanovic Z, Legrand O, Marie JP. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 2006 5 : 723 31.
9. Cai Z, Bao HY, Lin MF. Correlation between survivin mRNA expression and homoharringtonine induced apoptosis of malignant hematopoietic cells. Chin Med J (Engl) 2005 118 : 548 54.
10. Ye XJ, Lin MF. Homoharringtonine induces apoptosis of endothelium and down-regulates VEGF expression of K562 cells. J Zhejiang Univ Sci 2004 5 : 230 4.
11. Lou YJ, Jin J, Xu WL, Tong XM. Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly (ADP-ribose) polymerase (PARP). Am J Hematol 2004 76 : 199 204.
12. Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003 101 : 2940 54.
13. Schuringa JJ, Wierenga ATJ, Kruijer W, Vellenga E. Constitutive Stat3, Try705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 2000 95 : 3765 70.
14. Baskiewicz-Masiuk M, Machalinksi B. The role of STAT5 proteins in the proliferation and apoptosis of the CML and AML cells. Eur J Haematol 2004 72 : 420 9.
15. Biethahn S, Alves F, Wilde S, Hiddemann W, Spiekermann K. Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Exp Hematol 1999 27 : 885 94.
16. Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E. Regulation of constitutive STAT5 phosphorylation in acute myelogenous leukemia blasts. Leukemia 2001 15 : 1923 31.
17. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000 95 : 19 29.
18. Seidel HM, Lamb P, Rosen J. Pharmaceutical intervention in the JAK/STAT signaling pathway. Oncogene 2000 19 : 2645 56.
19. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000 19 : 2496 504.
20. Quentmeier H, MacLeod RAF, Zaborski M, Drexler HG. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006 20 : 471 6.
21. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997 159 : 4720 8.
22. Xiudi Yang, Chunmei Yang, Keding Shao, Xingnong Ye, Haitao Meng, Yuhong Zhou, Wenbin Qian. Refractory multiple myeloma treated with homoharringtonine: report of two cases. Ann Hematol 2007 86 : 919 21.
23. Xie SH, Wang Y, Liu JX, Sun T, Wilson MB, Smithgall TE, Arlinghaus RB. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 2001 20 : 6188 95.
24. Schiemann WP, Bartoe JL, Nathanson NM. Box 3-independent signaling mechanisms are involved in leukemia inhibitory factor receptor alpha- and gp130-mediated stimulation of mitogenactivated protein kinase: evidence for participation of multiple signaling pathways which converge at Ras. J Biol Chem 1997 272 : 16631 6.
25. Mizuguchi R, Hatakeyama M. Conditional activation of Janus kinase (JAK) confers factor independence upon interleukin-3-dependent cells: essential role of Ras in JAK-triggered mitogenesis. J Biol Chem 1998 273 : 32297 303.
26. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 2006 66 : 6468 72.
27. Meng S, Chen Z, Munoz-Antonia T, Wu J. Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor. Biochem J. 2005 91 (Pt 1 143 51.
28. Arnaud M, Crouin C, Deon C, Loyaux D, Bertoglio J. Phosphorylation of Grb2-associated binder 2 on serine 623 by ERK MAPK regulates its association with the phosphatase SHP-2 and decreases STAT5 activation. J Immunol 2004 173 : 3962 71.